A detailed history of First Horizon Advisors, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 395,386 shares of BMY stock, worth $22.8 Million. This represents 0.57% of its overall portfolio holdings.

Number of Shares
395,386
Previous 103,773 281.01%
Holding current value
$22.8 Million
Previous $4.31 Million 374.84%
% of portfolio
0.57%
Previous 0.13%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 08, 2024

BUY
$39.66 - $51.75 $11.6 Million - $15.1 Million
291,613 Added 281.01%
395,386 $20.5 Million
Q2 2024

Jul 19, 2024

BUY
$40.25 - $52.99 $65,688 - $86,479
1,632 Added 1.6%
103,773 $4.31 Million
Q1 2024

Apr 26, 2024

BUY
$47.98 - $54.4 $419,009 - $475,075
8,733 Added 9.35%
102,141 $5.54 Million
Q4 2023

Feb 06, 2024

BUY
$48.48 - $57.85 $100,596 - $120,038
2,075 Added 2.27%
93,408 $4.79 Million
Q3 2023

Oct 27, 2023

SELL
$57.89 - $64.73 $370,959 - $414,789
-6,408 Reduced 6.56%
91,333 $5.3 Million
Q2 2023

Aug 03, 2023

SELL
$63.71 - $70.74 $34,913 - $38,765
-548 Reduced 0.56%
97,741 $6.25 Million
Q1 2023

May 15, 2023

BUY
$65.71 - $74.53 $547,035 - $620,462
8,325 Added 9.25%
98,289 $6.81 Million
Q4 2022

Feb 10, 2023

SELL
$68.48 - $81.09 $241,802 - $286,328
-3,531 Reduced 3.78%
89,964 $6.47 Million
Q3 2022

Nov 09, 2022

SELL
$0.13 - $76.84 $302 - $178,729
-2,326 Reduced 2.43%
93,495 $6.65 Million
Q2 2022

Aug 02, 2022

BUY
$72.62 - $79.98 $817,338 - $900,174
11,255 Added 13.31%
95,821 $7.38 Million
Q1 2022

May 10, 2022

SELL
$61.48 - $73.72 $50,229 - $60,229
-817 Reduced 0.96%
84,566 $6.18 Million
Q4 2021

Feb 09, 2022

SELL
$53.63 - $62.52 $5,041 - $5,876
-94 Reduced 0.11%
85,383 $5.32 Million
Q3 2021

Nov 15, 2021

BUY
$59.17 - $69.31 $325,079 - $380,789
5,494 Added 6.87%
85,477 $5.06 Million
Q3 2021

Nov 09, 2021

BUY
$59.17 - $69.31 $3.59 Million - $4.2 Million
60,596 Added 312.56%
79,983 $4.73 Million
Q2 2021

Aug 09, 2021

SELL
$61.91 - $67.42 $97,570 - $106,253
-1,576 Reduced 7.52%
19,387 $1.3 Million
Q1 2021

May 11, 2021

BUY
$59.34 - $66.74 $62,247 - $70,010
1,049 Added 5.27%
20,963 $1.32 Million
Q4 2020

Feb 11, 2021

BUY
$57.74 - $65.43 $15,763 - $17,862
273 Added 1.39%
19,914 $1.24 Million
Q3 2020

Nov 12, 2020

SELL
$57.43 - $63.64 $62,885 - $69,685
-1,095 Reduced 5.28%
19,641 $1.18 Million
Q2 2020

Jul 31, 2020

BUY
$54.82 - $64.09 $136,501 - $159,584
2,490 Added 13.65%
20,736 $1.22 Million
Q1 2020

May 05, 2020

SELL
$46.4 - $67.43 $97,300 - $141,400
-2,097 Reduced 10.31%
18,246 $1.02 Million
Q4 2019

Jan 07, 2020

BUY
$49.21 - $64.19 $14,270 - $18,615
290 Added 1.45%
20,343 $1.31 Million
Q3 2019

Oct 23, 2019

BUY
$42.77 - $50.71 $220,778 - $261,765
5,162 Added 34.67%
20,053 $1.02 Million
Q2 2019

Aug 05, 2019

BUY
$44.62 - $49.34 $177,498 - $196,274
3,978 Added 36.45%
14,891 $0
Q1 2019

Apr 26, 2019

SELL
$45.12 - $53.8 $141,496 - $168,716
-3,136 Reduced 22.32%
10,913 $0
Q4 2018

Feb 11, 2019

SELL
$48.76 - $63.23 $209,668 - $271,889
-4,300 Reduced 23.43%
14,049 $730,000
Q3 2018

Nov 05, 2018

BUY
$55.19 - $62.25 $962,568 - $1.09 Million
17,441 Added 1920.81%
18,349 $0
Q3 2018

Nov 05, 2018

SELL
$55.19 - $62.25 $1 Million - $1.13 Million
-18,154 Reduced 95.24%
908 $0
Q2 2018

Aug 07, 2018

BUY
$50.53 - $62.98 $345,170 - $430,216
6,831 Added 55.85%
19,062 $0
Q1 2018

May 02, 2018

BUY
$59.92 - $68.98 $3,655 - $4,207
61 Added 0.5%
12,231 $0
Q4 2017

Jan 25, 2018

SELL
$59.94 - $65.35 $35,184 - $38,360
-587 Reduced 4.6%
12,170 $0
Q2 2017

Aug 14, 2017

BUY
N/A
12,757
12,757 $0

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track First Horizon Advisors, Inc. Portfolio

Follow First Horizon Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Horizon Advisors, Inc. with notifications on news.